Skip to main content

Lower Urinary Tract Symptoms

10
Pipeline Programs
10
Companies
13
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
2
7
1
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

9 companies ranked by most advanced pipeline stage

Laborie
LaborieNH - Portsmouth
3 programs
1
Urodynamics + TETRA - NIRSPhase 41 trial
Fully integrated Uro-NIRS:UDSN/A1 trial
Peritron+N/A1 trial
Active Trials
NCT00706407Completed42Est. May 2010
NCT02673944Completed10Est. Mar 2016
NCT00871975Terminated155Est. Feb 2012
Biocorp
BiocorpFrance - Issoire
4 programs
1
3
MCS-2Phase 31 trial
MCS-2Phase 31 trial
MCS-2Phase 31 trial
MCS-2 15 mg/dayPhase 2/31 trial
Active Trials
NCT01002417Completed274Est. Feb 2014
NCT01002664Completed272Est. Jun 2014
NCT01002222Completed200Est. Feb 2014
+1 more trials
Health Ever Bio-Tech
Health Ever Bio-TechTaiwan - Taipei
4 programs
1
3
MCS-2Phase 3
MCS-2Phase 3
MCS-2Phase 3
MCS-2 15 mg/dayPhase 2/3
Jeil Pharmaceutical
Jeil PharmaceuticalKorea - Seoul
1 program
1
Tamsulosin 0.2mg + Solifenacin 5mgPhase 31 trial
Active Trials
NCT02972268Completed780Est. Aug 2018
Boehringer Ingelheim
Boehringer IngelheimINGELHEIM, Germany
2 programs
tamsulosinPHASE_21 trial
tamsulosin hydrochloridePHASE_21 trial
Active Trials
NCT01726270Completed689Est. Mar 2013
NCT02244281Completed74
Forte Biosciences
1 program
Midstream urine collection deviceN/A1 trial
Active Trials
NCT03729336Completed74Est. Jun 2019
Francis Medical
Francis MedicalMN - Maple Grove
1 program
MirabegronN/A
Pfizer
PfizerNEW YORK, NY
1 program
Pharmacist review of LUTSN/A1 trial
Active Trials
NCT04331340Completed64Est. Aug 2024
Recordati
RecordatiFrance - Saint-Victor
1 program
NX-1207PHASE_31 trial
Active Trials
NCT02003742Terminated104Est. Jan 2015

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
LaborieUrodynamics + TETRA - NIRS
Jeil PharmaceuticalTamsulosin 0.2mg + Solifenacin 5mg
RecordatiNX-1207
BiocorpMCS-2
BiocorpMCS-2
BiocorpMCS-2
BiocorpMCS-2 15 mg/day
Boehringer Ingelheimtamsulosin
Boehringer Ingelheimtamsulosin hydrochloride
PfizerPharmacist review of LUTS
Forte BiosciencesMidstream urine collection device
LaboriePeritron+
LaborieFully integrated Uro-NIRS:UDS

Clinical Trials (13)

Total enrollment: 2,918 patients across 13 trials

NCT00871975LaborieUrodynamics + TETRA - NIRS

Tetra-NIRS Clinical Study

Start: Apr 2009Est. completion: Feb 2012155 patients
Phase 4Terminated
NCT02972268Jeil PharmaceuticalTamsulosin 0.2mg + Solifenacin 5mg

Clinical Trial to Compare the Solifenacin/Tamsulosin Combination Therapy With Tamsulosin Monotherapy for LUTS Due to BPH

Start: Feb 2016Est. completion: Aug 2018780 patients
Phase 3Completed

Efficacy and Safety of a Single TRUS-guided Intraprostatic Injection of NX-1207 in Patients With LUTS Due to BPH

Start: Sep 2013Est. completion: Jan 2015104 patients
Phase 3Terminated

Open-Label Extension Study of MCS-2 in the Treatment of Lower Urinary Tract Symptoms (MCS-2-US-c)

Start: Jan 2011Est. completion: Feb 2014200 patients
Phase 3Completed

Open-Label Extension Study of MCS-2 in the Treatment of Lower Urinary Tract Symptoms

Start: Aug 2010Est. completion: Jun 2014180 patients
Phase 3Completed

Efficacy and Safety of MCS-2 in the Treatment of Lower Urinary Tract Symptoms

Start: May 2010Est. completion: Jun 2014272 patients
Phase 3Completed
NCT01002417BiocorpMCS-2 15 mg/day

MCS in the Treatment of Lower Urinary Tract Symptoms

Start: Jul 2010Est. completion: Feb 2014274 patients
Phase 2/3Completed

An 8-week, Open-label, Uncontrolled Study of Tamsulosin 0.4mg in Men With Bothersome Urinary Symptoms

Start: Nov 2012Est. completion: Mar 2013689 patients
Phase 2Completed
NCT02244281Boehringer Ingelheimtamsulosin hydrochloride

Study of FLOMAX® Versus Placebo in Female Patients With Lower Urinary Tract Symptoms (LUTS) With a Significant Component of Voiding Symptoms

Start: May 200174 patients
Phase 2Completed
NCT04331340PfizerPharmacist review of LUTS

Management of LUTS by Community Pharmacists

Start: Apr 2021Est. completion: Aug 202464 patients
N/ACompleted
NCT03729336Forte BiosciencesMidstream urine collection device

PEEZY Midstream Urine Device Compared to Catheterized Urine Sample

Start: Feb 2019Est. completion: Jun 201974 patients
N/ACompleted

Portable Pves Study

Start: Jan 2016Est. completion: Mar 201610 patients
N/ACompleted
NCT00706407LaborieFully integrated Uro-NIRS:UDS

Uro-NIRS Clinical Study

Start: Apr 2008Est. completion: May 201042 patients
N/ACompleted

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

7 late-stage (Phase 3) programs, potential near-term approvals
10 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.